外周血中性粒细胞与淋巴细胞比值对老年转移性食管癌免疫治疗预后的影响

doi:10.3969/j.issn.1003-9198.2024.02.015

Abstract

Abstract: Objective To evaluate the predictive value of peripheral blood neutrophil/lymphocyte ratio(NLR) on the prognosis of the elderly patients with metastatic esophageal cancer who received immunotherapy. Methods The clinical data of 116 elderly patients with metastatic esophageal cancer before immunotherapy were retrospectively analyzed. The optimal critical value of NLR was determined by X-tile software, and single factor and multiple factor Cox regression model was used to analyze the influencing factors for prognosis. Kaplan-Meier method was used to plot survival curves for relevant risk factors. Results The optimal threshold value of NLR before treatment was 2.8, according to which the patients were divided into low NLR group and high NLR group. Cox regression showed that NLR and Eastern Cooperative Oncology Group(ECOG) score before treatment were the independent risk factors for the prognosis of the elderly patients with metastatic esophageal cancer after immunotherapy. NLR<2.8 before treatment was associated with longer progression free survival (PFS) (P<0.001) and longer overall survival (OS) (P<0.001). Conclusions The NLR level can predict the efficacy of immunotherapy in the elderly patients with metastatic esophageal cancer, and may be a simple, economical, and effective prognostic indicator.

Key words: neutrophil/lymphocyte ratio, esophageal cancer, immunotherapy, prognosis

CLC Number:

R 735.1

ZHU Wugang, ZHAI Chentong, LIU Degan, XU Wenjing. Predictive value of peripheral blood neutrophil to lymphocyte ratio on prognosis for elderly patients with metastatic esophageal cancer after immunotherapy[J]. Practical Geriatrics, 2024, 38(2): 171-175.

References

[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[3] ZENG H, CHEN W, ZHENG R, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6(5): e555-e567.
[4] HUANG S, ZHENG S, GONG T,et al. Survival benefit evaluation of radiotherapy in esophageal cancer patients aged 80 and older[J]. Oncotarget, 2017, 8(67):112094-112102.
[5] MCDERMOTT D F, ATKINS M B. PD-1 as a potential target in cancer therapy[J]. Cancer Med, 2013, 2(5): 662-673.
[6] RIBAS A, WOLCHOK J D. Cancer immunotherapy using checkpoint blockade[J]. Science, 2018, 359(6382): 1350-1355.
[7] PARDOLL D M. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012, 12(4): 252-264.
[8] TOPALIAN S L, HODI F S, BRAHMER J R, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med, 2012, 366(26):2443-2454.
[9] NEGRAO M V, LAM V K, REUBEN A, et al. PD-L1 expression, tumor mutational burden, and cancer gene mutations are stronger predictors of benefit from immunecheckpoint blockade than HLA class I genotype in non-small cell lung cancer[J]. J Thorac Oncol, 2019, 14(6): 1021-1031.
[10] MANTOVANI A, ALLAVENA P, SICA A, et al. Cancer-related inflammation[J]. Nature, 2008, 454(7203): 436-444.
[11] GRETEN F R, GRIVENNIKOV S I. Inflammation and cancer: triggers, mechanisms, and consequences[J]. Immunity, 2019, 51(1): 27-41.
[12] DIAKOS C I, CHARLES K A, MCMILLAN D C, et al. Cancer-related inflammation and treatment effectiveness[J]. Lancet Oncol, 2014, 15(11): e493-e503.
[13] 叶韬, 盛桂凤, 董益忠, 等. 中性粒细胞淋巴细胞比值(NLR)与晚期非小细胞肺癌一线化疗疗效及预后的关系[J]. 现代肿瘤医学, 2021, 29(12):2076-2081.
[14] MOUCHLI M, REDDY S, GERRARD M, et al. Usefulness of neutrophil-to-lymphocyte ratio(NLR) as a prognostic predictor after treatment of hepatocellular carcinoma. Review article[J]. Ann Hepatol, 2021, 22: 100249.
[15] XIANG Z, HU T, WANG Y, et al. Neutrophil-lymphocyte ratio(NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma(PDAC)[J]. Biosci Rep, 2020, 40(6):BSR20201190.
[16] 郭术楠.NLR、PLR、LMR在老年食管癌根治性放化疗患者预后中的分析[D]. 蚌埠:蚌埠医学院, 2021. DOI:10.26925/d.cnki.gbbyc.2021.000193.
[17] 刘思凡, 姜娜, 丁雪丽, 等. 放(或/和)化疗前NLR、SII、PNI对进展期食管癌患者预后的预测价值[J]. 胃肠病学和肝病学杂志, 2021, 30(12):1325-1330.
[18] SEYMOUR L, BOGAERTS J, PERRONE A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics[J]. Lancet Oncol, 2017, 18(3): e143-e152.
[19] 国家卫生健康委员会.食管癌诊疗规范(2018年版)[J].中华消化病与影像杂志:电子版, 2019, 9(4):158-192.
[20] SUN J M, SHEN L, SHAH M A, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer(KEYNOTE-590): a randomised, placebo-controlled, phase 3 study[J]. Lancet, 2021, 398(10302): 759-771.
[21] DOKI Y, AJANI J A,KATO K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma[J]. N Engl J Med, 2022, 386(5): 449-462.
[22] LUO H, LU J, BAI Y, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial[J]. JAMA, 2021, 326(10): 916-925.
[23] CHEN Z, WANG K, LU H, et al. Systemic inflammation response index predicts prognosis in patients with clear cell renal cell carcinoma: a propensity score-matched analysis[J]. Cancer Manag Res, 2019, 11:909-919.
[24] BREMNES R M, BUSUND L T,KILVÆR T L, et al. The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung cancer[J]. J Thorac Oncol, 2016, 11(6): 789-800.
[25] CAMP R L, DOLLED-FILHART M, RIMM D L. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization[J]. Clin Cancer Res, 2004, 10(21): 7252-7259.

Predictive value of peripheral blood neutrophil to lymphocyte ratio on prognosis for elderly patients with metastatic esophageal cancer after immunotherapy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 9

Metrics

Recommended 10

[1]	WANG Xinping, XIE Baimei, WEI Guo, YE Xiaoli, ZHAO Yayun, TAN Xiaotian. Expression levels and clinical significance of serum S100A9 and sCD163 in elderly patients with idiopathic interstitial pneumonia [J]. Practical Geriatrics, 2024, 38(8): 802-807.
[2]	XUE Bingyan, XU Ruitong, GU Danyang, ZHU Guoqin. Correlation analysis of clinicopathologic features and prognosis in eighty-one elderly patients with pancreatic neuroendocrine tumors [J]. Practical Geriatrics, 2024, 38(7): 718-721.
[3]	CHEN Tufen, ZHANG Bo. Analysis of clinical and serological characteristics of hepatitis E in 50 elderly patients [J]. Practical Geriatrics, 2024, 38(7): 722-726.
[4]	DU Zhaona, JIANG Wenbo, MOU Junyu, YU Chengyun, XIA Wei. Risk factors and prognosis of new continuous complete left bundle branch block in elderly patients undergoing transcatheter aortic valve replacement [J]. Practical Geriatrics, 2024, 38(5): 500-437.
[5]	PENG Zetong, ZHANG Yao, LIU Bin. Analysis of the effects of anemia on death in elderly patients with community-acquired pneumonia [J]. Practical Geriatrics, 2024, 38(3): 260-264.
[6]	CHEN Lu, YAO Junying, YU Yongyun, FAN Min. Effect of MDT immunonutritional support therapy in elderly patients undergoing craniocerebral surgery [J]. Practical Geriatrics, 2024, 38(3): 278-282.
[7]	LI Guangyao, YE Bihua, LI Xiaoliang, TANG Qin, LIU Cuihua. Relationship of ApoB/ApoA1 ratio and triglyceride glucose index with severity and prognosis of traumatic brain injury in the elderly [J]. Practical Geriatrics, 2024, 38(10): 1049-1053.
[8]	ZHANG Ming, CHEN Xi, LIU Yuehong, XIE De, WANG Zhicong, LAN Pingwen, WANG Guanglin. Relationship between red blood cell volume distribution width and prognosis of elderly patients with hip fracture [J]. Practical Geriatrics, 2024, 38(1): 22-27.
[9]	SUN Jie, ZHA Xiufang, XU Jin, ZHAO Junning, HE Wei, ZHANG Nannan. Correlation of AHNAK expression with macrophage infiltration and prognosis in patients with gastric cancer [J]. Practical Geriatrics, 2024, 38(1): 49-53.